Nucleic Acid, Nucleoside, or Nucleotide – Page 16

Gritstone Cancer Vaccine Trial Misses Primary Endpoint, Stock Plummets

1 year ago talkbio0Tagged Circulating, Circulating Tumor DNA, Colorectal Carcinoma, Gritstone, Personalized Neoantigen Cancer Vaccine, Phase 2 Clinical Trials, Progression-Free Survival, Stock Market Reaction

Gritstone, Personalized Neoantigen Cancer Vaccine, Colorectal Cancer, Phase 2 Study Failure, Circulating Tumor DNA (ctDNA), Progression-Free Survival (PFS), Stock Market Reaction

Groundbreaking Data Revealed for Genetic Epilepsy Drug STK-001 by Stoke Therapeutics, Exhilarating Investors

1 year ago talkbio0Tagged Antisense Oligonucleotides, Genetic Epilepsy Drug, Infantile Severe Myoclonic Epilepsy, investor, Level of interest, Positive Clinical Trial, Seizures, STK-001, Stoke

Stoke Therapeutics, STK-001, Genetic Epilepsy Drug, Dravet Syndrome, Antisense Oligonucleotide, Seizure Reduction, Positive Clinical Trial Data, Investor Enthusiasm

Boundless Bio, Oncology Startup Targeting Extrachromosomal DNA, Files for $100 Million IPO

2 years ago talkbio0Tagged Arch of foot, Backed, Bayer, bleomycin/dacarbazine/lomustine/vincristine, Boundless, Checkpoint Kinase 1 Inhibitors, extrachromosomal DNA, IPO, Nasdaq Listing, Oncology Startup, Partner in relationship, Phase 1 Trials, Preliminary, Public Offering, Second Half of 2024, small molecule drugs, symbol

Boundless Bio, Oncology Startup, Initial Public Offering (IPO), Extrachromosomal DNA (ecDNA), Small Molecule Drugs (ecDTx), Checkpoint Kinase 1 Inhibitors, Phase 1 Trials, Nasdaq Listing (Symbol: BOLD), Backed by Bayer and Arch Venture Partners, Preliminary Data Expected in Second Half of 2024

Takeda Appoints Former CRISPR CMO Phuong Khanh (PK) Morrow to Lead Oncology R&D Amidst Pipeline Pruning

2 years ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, PK

Clustered Regularly Interspaced Short Palindromic Repeats, PK